FREQUENCY OF IMMUNOHISTOCHEMICAL EXPRESSION OF HER2 IN PROSTATIC ADENOCARCINOMA

  • Iqra Ahmad Shah Combined Military Hospital (National University of Medical Sciences), Multan Pakistan
  • Shagufta Iram Combined Military Hospital (National University of Medical Sciences), Multan Pakistan
  • Unaiza Jamil Combined Military Hospital (National University of Medical Sciences), Multan Pakistan
  • Ayesha Haider Combined Military Hospital (National University of Medical Sciences), Multan Pakistan

Abstract

Objective: To determine the frequency of immunohistochemical expression of HER2 in prostatic adenocarcinoma.

Material and Method: This Descriptive, cross sectional study was conducted in the Department of Histopathology, Combined Military Hospital, Multan from August 2017 to Feb 2018. A total of 90 cases of prostate adenocarcinoma were included in the study. Demographic and clinical data were recorded. Data was analyzed by using SPSS version 21. Frequency and percentage were calculated for the result of HER2 expression. Mean ± standard deviation (SD) was calculated for age. Effect modifiers like age and duration of disease were controlled by stratification. Chi-square test was applied. p-value ≤ 0.05 was taken as statistically significant.

Results: Out of 90 patients of prostate adenocarcinoma, the age of the patients was between 45-85 years with a mean age of 62.57+13.151 years. Of these, 45 patients had duration of disease between 1-2 years (50%) and 45 patients had shown duration of disease between 3-4 years (50%). Of these, 65 (72.2%) cases of prostate adenocarcinoma were negative for HER2 and 25 (27.8%) cases showed positivity 0f +2 and+3 for HER2. There was no significant difference in HER2 expression between groups based on age and disease duration.

Conclusion: The increased expression of HER2 in prostate adenocarcinoma suggests its prognostic utility. The trastuzumab therapy (antibody against HER2) is currently available and can be used as a therapeutic target in HER2 positive prostate adenocarcinoma thus improving the prognosis of patients.   

Key Words: Prostate adenocarcinoma, Imuunohistochemical expression, HER2.

Published
2020-04-01